| scholarly article | Q13442814 |
| P2093 | author name string | Zheng Wang | |
| Yan Fang | |||
| Li Zhu | |||
| Kunwei Shen | |||
| Ou Huang | |||
| Weiguo Chen | |||
| Xiaosong Chen | |||
| Jianrong He | |||
| Jiayi Wu | |||
| Yafen Li | |||
| P2860 | cites work | A Prospective Analysis of Implementation of Multi-Disciplinary Team Decisions in Breast Cancer | Q57545796 |
| Analysis of clinical decision-making in multi-disciplinary cancer teams | Q57545915 | ||
| Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer | Q57578316 | ||
| Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers | Q59487524 | ||
| Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group | Q72234622 | ||
| Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy | Q87732217 | ||
| Trastuzumab containing regimens for early breast cancer | Q24200192 | ||
| High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | Q34484185 | ||
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer | Q35038093 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women | Q35921297 | ||
| Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network | Q36589035 | ||
| Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. | Q37138269 | ||
| Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study | Q37627696 | ||
| Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. | Q38485006 | ||
| Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. | Q38670254 | ||
| Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab | Q39532324 | ||
| Future of cancer incidence in the United States: burdens upon an aging, changing nation | Q39983611 | ||
| Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer | Q43250044 | ||
| 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial | Q47973074 | ||
| Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas | Q48111542 | ||
| P433 | issue | 9 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 2602-2609 | |
| P577 | publication date | 2020-02-14 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients | |
| P478 | volume | 11 |
Search more.